Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Casirivimab/imdevimab  COVID-19 treatment studies for Casirivimab/i..  C19 studies: Casirivimab/i..  Casirivimab/i..   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Further treatment inclu.. 58% Improvement Relative Risk c19early.org/r Kakinoki et al. Casirivimab/i.. for COVID-19 EARLY Favors casirivimab/im.. Favors control
Impact of Antibody Cocktail Therapy Combined with Casirivimab and Imdevimab on Clinical Outcome for Covid-19 patients in A Real-Life Setting: A Single Institute Analysis
Kakinoki et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2022.01.067 (date from earlier preprint)
Kakinoki et al., Impact of Antibody Cocktail Therapy Combined with Casirivimab and Imdevimab on Clinical Outcome for Covid-19.., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2022.01.067 (date from earlier preprint)
Nov 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 55 patients in Japan treated a median of 3 days from symptom onset with casirivimab/imdevimab, and 53 control patients, showing lower risk of further treatment including oxygen or antivirals.
Efficacy is variant dependent. In Vitro research suggests a lack of efficacy for omicron [Liu, Sheward, Tatham, VanBlargan].
risk of further treatment including oxygen or antivirals, 57.6% lower, RR 0.42, p = 0.049, treatment 13 of 55 (23.6%), control 22 of 53 (41.5%), NNT 5.6, adjusted per study, odds ratio converted to relative risk, multivariable.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Kakinoki et al., 4 Nov 2021, retrospective, Japan, peer-reviewed, 16 authors, average treatment delay 3.0 days.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperCasirivimab/i..All
Abstract: Journal Pre-proof Impact of Antibody Cocktail Therapy Combined with Casirivimab and Imdevimab on Clinical Outcome for Covid-19 patients in A Real-Life Setting: A Single Institute Analysis Yasutaka Kakinoki , Kazuki Yamada , Yoko Tanino , Keiko Suzuki , Takaya Ichikawa , Naoki Suzuki , Go Asari , Ai Nakamura , Shin Kukita , Akito Uehara , Seisuke Saito , Shohei Kuroda , Hidemitsu Sakagami , Yuuki Nagashima , Kae Takahashi , Satoshi Suzuki PII: DOI: Reference: S1201-9712(22)00076-5 https://doi.org/10.1016/j.ijid.2022.01.067 IJID 5989 To appear in: International Journal of Infectious Diseases Received date: Revised date: Accepted date: 10 December 2021 18 January 2022 30 January 2022 Please cite this article as: Yasutaka Kakinoki , Kazuki Yamada , Yoko Tanino , Keiko Suzuki , Takaya Ichikawa , Naoki Suzuki , Go Asari , Ai Nakamura , Shin Kukita , Akito Uehara , Seisuke Saito , Shohei Kuroda , Hidemitsu Sakagami , Yuuki Nagashima , Kae Takahashi , Satoshi Suzuki , Impact of Antibody Cocktail Therapy Combined with Casirivimab and Imdevimab on Clinical Outcome for Covid-19 patients in A Real-Life Setting: A Single Institute Analysis, International Journal of Infectious Diseases (2022), doi: https://doi.org/10.1016/j.ijid.2022.01.067 This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. © 2022 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/) Highlights for review  Covid-19 patients with high-risk factors in a real-life practice were analyzed.  The cocktail combined with casirivimab and imdevimab was given consecutively.  The efficacy was compared with those patients without the cocktail.  The cocktail significantly reduced 70% in need of additional medical intervention. Impact of Antibody Cocktail Therapy Combined with Casirivimab and Imdevimab on Clinical Outcome for Covid-19 patients in A Real-Life Setting: A Single Institute Analysis Yasutaka Kakinoki, MD, PhD1), Kazuki Yamada, MD 1), Yoko Tanino, MD 1), Keiko Suzuki, MD 1), Takaya Ichikawa, MD 1), Naoki Suzuki, MD 2), Go Asari, BA 2), Ai Nakamura, MD 1), Shin Kukita, MD 1), Akito Uehara, MD 1), Seisuke Saito, MD 1), Shohei Kuroda, MD 1), Hidemitsu Sakagami, MD 1), Yuuki Nagashima, MD 1), Kae Takahashi, MD 1), and Satoshi Suzuki, MD 1) 1) Division of Internal Medicine, Asahikawa City Hospital, Asahikawa, Japan 2) Asahikawa City Health Center, Asahikawa, Japan Corresponding author: Yasutaka Kakinoki, MD, PhD. Asahikawa City Hospital, 1-1-65, Kinseicho, Asahikawa, 070-8610, Japan e-mail: y_kakinoki@ach.hokkaido.jp Keywords: Covid-19; SARS-CoV-2; cocktail; ronapreve; REGEN-COV ABSTRACT Background. Recent data from clinical trials suggest that antibody cocktail therapy with casirivimab and imdevimab is linked to reduction of the risk of hospitalization or death among high-risk patients with..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit